JPMorgan Chase & Co’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $134 | Sell |
50
-245
| -83% | -$657 | ﹤0.01% | 5921 |
|
|
2025
Q1 | $2.37K | Sell |
295
-60
| -17% | -$482 | ﹤0.01% | 5653 |
|
|
2024
Q4 | $3.43K | Buy |
355
+260
| +274% | +$2.51K | ﹤0.01% | 5523 |
|
|
2024
Q3 | $1.76K | Sell |
95
-199
| -68% | -$3.69K | ﹤0.01% | 5569 |
|
|
2024
Q2 | $4.89K | Sell |
294
-1,018
| -78% | -$16.9K | ﹤0.01% | 5373 |
|
|
2024
Q1 | $22.8K | Sell |
1,312
-14,554
| -92% | -$253K | ﹤0.01% | 5207 |
|
|
2023
Q4 | $248K | Sell |
15,866
-30,133
| -66% | -$471K | ﹤0.01% | 4323 |
|
|
2023
Q3 | $2.27M | Sell |
45,999
-1,598
| -3% | -$79K | ﹤0.01% | 2923 |
|
|
2023
Q2 | $3.72M | Buy |
47,597
+4,744
| +11% | +$371K | ﹤0.01% | 2682 |
|
|
2023
Q1 | $3.88M | Buy |
42,853
+1,025
| +2% | +$92.9K | ﹤0.01% | 2609 |
|
|
2022
Q4 | $4.94M | Buy |
41,828
+15,344
| +58% | +$1.81M | ﹤0.01% | 2379 |
|
|
2022
Q3 | $4.81M | Sell |
26,484
-7,247
| -21% | -$1.32M | ﹤0.01% | 2365 |
|
|
2022
Q2 | $3.03M | Buy |
33,731
+518
| +2% | +$46.5K | ﹤0.01% | 2745 |
|
|
2022
Q1 | $5.16M | Buy |
33,213
+7,204
| +28% | +$1.12M | ﹤0.01% | 2536 |
|
|
2021
Q4 | $7.74M | Sell |
26,009
-6,491
| -20% | -$1.93M | ﹤0.01% | 2273 |
|
|
2021
Q3 | $18.7M | Sell |
32,500
-2,484
| -7% | -$1.43M | ﹤0.01% | 1607 |
|
|
2021
Q2 | $15.9M | Buy |
34,984
+13,310
| +61% | +$6.04M | ﹤0.01% | 1799 |
|
|
2021
Q1 | $11.7M | Buy |
21,674
+21,323
| +6,075% | +$11.5M | ﹤0.01% | 2007 |
|
|
2020
Q4 | $310K | Buy |
351
+60
| +21% | +$53K | ﹤0.01% | 3997 |
|
|
2020
Q3 | $180K | Buy |
+291
| New | +$180K | ﹤0.01% | 3784 |
|